Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 5, 2015, Pages 5642-5649

  Liew, Phui Ly ^a,b   Hsu, Chun Sen ^c   Liu, Wei Min ^d   Lee, Yu Chieh ^e   Lee, Yi Chih ^f   Chen, Chi Long ^b,d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f CHING YUN UNIVERSITY   (Taiwan)

Author keywords

E Cadherin; Keap1; Nrf2; Ovarian cancer; P16

Indexed keywords

CADHERIN; CDH1 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; KEAP1 PROTEIN, HUMAN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; NFE2L2 PROTEIN, HUMAN; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR NRF2; TUMOR MARKER;

ADULT; AGE; AGED; CANCER STAGING; CHEMISTRY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TISSUE MICROARRAY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CADHERINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; NF-E2-RELATED FACTOR 2; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 84937910008     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Kurman RJ, Carcangiu ML, Herrington CS and Young RH. World Health Organization Classification of Tumours of Female Reproductive Organs. 4th edition. Lyon: IARC Press; 2014.
2. Li Y, Paonessa JD and Zhang Y. Mechanism of chemical activation of Nrf2. PLos One 2012; 7: e 35122.
3. Lau A, Villeneuve NF, Sun Z, Wong PK and Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res 2008; 58: 262-270.
4. Itoh K, Mimura J and Yamamoto M. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal 2010; 13: 1665-78.
5. Hayes JD, Mc Mahon M, Chowdhry S and Dinkova-Kostova AT. Cancer chemoprevention mechanism mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal 2010; 13: 1713-48.
6. Taguchi K, Motohashi H and Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 2011; 16: 123-40.
7. Stepkowski TM and Kruszewski MK. Molecular cross-talk between the Nrf2/ Keap1 signaling pathway, autophagy, and apoptosis. Free Radic Biol Med 2011; 50: 1186-95.
8. Yagi T and Takeichi M. Cadherin superfamily genes: functions, genomic organization, and neurologic diversity. Genes Dev 2000; 14: 1169-80.
9. Rao RK, Basuroy S, Rao VU, Karnaky KJ, Jr and Gupta A. Tyrosine phosphorylation and dissociation of occluding-ZO-1 and E-cadherin-beta-catenin complexes from the cytoskeleton by oxidative stress. Biochem J 2002; 368: 471-81.
10. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y and Johnson KR. Cadherin switching. J Cell Sci 2008; 15: 727-35.
11. Li Y, Chen CQ, He YL, Cai SR, Yang DJ, He WL, Xu JB and Zan WH. Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis in gastric carcinoma. J Surg Oncol 2012; 106: 304-10.
12. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ and Choi W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009; 69: 5820-8.
13. Kim WD, Kim YW, Cho IJ, Lee CH and Kim SG. E-cadherin inhibits nuclear accumulation of Nrf2: implications for chemoresistance of cancer cells. J Cell Sci 2012; 125: 1284-95.
14. Romagosa C, Simonetti S, Lopez-Vicente L, Mazo A, Lleonart MW, Castellvi J and Ramony Cajal S. p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene 2011; 30: 2087-2097.
15. Je EM, An CH, Yoo NJ and Lee SH. Mutational and expressional analyses of Nrf2 and Keap1 in sarcomas. Tumori 2012; 98: 540-5.
16. Hanada N, Takahata T, Zhou Q, Ye X, Sun R, Itoh J, Ishiguro A, Kijima H, Mimura J, Itoh K, Fukuda S and Saijo Y. Methylation of the Keap1 gene promoter region in human colorectal cancer. BMC Cancer 2012; 12: 66.
17. Merikallio H, Pääkkö P, Kinnula VL, Harju T and Soini Y. Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer. Hum Pathol 2012; 43: 577-84.
18. Shibata Y, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M and Hirohashi S. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 2008; 135: 1358-1368.
19. Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN, Minna JD, Stewart DJ and Wistuba II. Nrf2 and Keap1 Abnormalities in Non-Small Cell Lung Carcinoma and Association with Clinicopathologic Features. Clin Cancer Res 2010; 16; 3743-53.
20. Kim YR, Oh JE, Kim MS, Kang MR, Park SW, Han YJ, Eom HS, Yoo NJ and Lee SH. Oncogenic NRF2 mutations in squamous cell carcinomas of esophagus and skin. J Pathol 2010; 220: 446-51.
21. Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W, and Zhang DD. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res 2010; 70: 5486-96.
22. van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, Vergote I, Mathijssen RH, Berns EM, Verweij J, Pothof J and Wiemer EA. miR-141 regulate Keap1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 2013; 32: 4284-92.
23. Manandhar S, Choi BH, Jung KA, Ryoo IG, Song M, Kang SJ, Choi HG, Kim JA, Park PH, Kwak MK. NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity. Free Radic Biol Med 2012; 52: 773-85.
24. Bao LJ, Jaramillo MC, Zhang ZB, Zheng YX, Yao M, Zhang DD and Yi XF. Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma. Int J Clin Exp Pathol 2014; 15: 1502-13.
25. Liao H, Zhou Q, Zhang Z, Wang Q, Sun Y, Yi X, Feng Y. NRF2 is overexpressed in ovarian epithelial carcinoma and is regulated by gonadotrophin and sex-steroid hormones. Oncol Rep 2012; 27: 1918-24.
26. Zhang Z, Wang Q, Ma J, Yi X, Zhu Y, Xi X, Feng Y, Jin Z. Reactive oxygen species regulate FSH-induced expression of vascular endothelial growth factor via Nrf2 and HIF1a signaling in human epithelial ovarian cancer. Oncol Rep 2013; 29: 1429-34.
27. Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, Grammatikos AP, Hecht JL and Cannistra SA. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res 2011; 71: 5081-9.
28. Wong TF, Yoshinaga K, Monma Y, Ito K, Niikura H, Nagase S, Yamamoto M and Yaegashi N. Association of Keap1 and Nrf2 generic mutations and polymorphisms with endometrioid endometrial adenocarcinoma survival. Int J Gynecol Cancer 2011; 21: 1428-35.
29. Ho CM, Chang WF, Lin MC, Chen TC, Huang SH, Liu FS, Chang Chein CC, Yu MH, Wang TY and Hsieh CY. Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma. Int J Gynecol Cancer 2010; 20: 1490-7.
30. O'Neill CJ, McBride HA, Connolly LE, Deavers MT, Malpica A and McCluggage WG. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology 2007; 50: 773-779.
31. Bhagat R, Kumar SS, Vaderhobli S, Premalata CS, Pallavi VR, Ramesh G, Krishnamoorthy L. Epigenetic alteration of p16 and retinoic acid receptor beta genes in the development of epithelial ovarian carcinoma. Tumour Biol 2014; 35: 9069-78.
32. Milea A, George SH, Matevski D, Jiang H, Madunic M, Berman HK, Gauthier ML, Gallie B, Shaw PA. Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma. Mod Pathol 2014; 27: 991-1001.
33. Zeppernick F, Ardighieri L, Hannibal CG, Vang R, Junge J, Kjaer SK, Zhang R, Kurman RJ, Shih IeM. BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors. Am J Surg Pathol 2014; 38: 1603-11.